We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Plasma Metabolite Profile and Gut Microbiota Connected to Obesity

By LabMedica International staff writers
Posted on 14 Mar 2018
A new link has been discovered between gut bacteria and obesity. More...
It has been found that certain amino acids in the blood can be connected to both obesity and the composition of the gut microbiome.

Emerging evidence has related the gut microbiome and circulating metabolites to human obesity. Gut microbiota is responsible for several metabolic functions and altered plasma metabolome may reflect differences in the gut microbiome.

Scientists at Lund University (Malmö, Sweden) analyzed blood plasma and stool samples from participants in the Malmö Offspring Study (MOS). Targeted profiling of 48 plasma metabolites was performed in a population of 920 Swedish adults (mean age 39 years, 53% were women) using targeted liquid chromatography-mass spectrometry. Gut microbiota was analyzed by sequencing of the16S rRNA gene (V1-V3 region) in fecal samples of 674 study participants.

The scientists reported that body mass index (BMI) was associated with 19 metabolites, of which glutamate provided the strongest direct association. By orthogonal partial least squares regression a metabolite principal component predictive of BMI was constructed (PCBMI). In addition to glutamate, PCBMI was dominated by branched chain amino acids (BCAA) and related metabolites. Four gut microbiota genera in the Lachnospiraceae family: L. blautia, L. dorea, L. ruminococcus and SHA-98) were associated with both BMI and PCBMI . When simultaneously regressing the PCBMI and the metabolite associated gut bacteria against BMI, only PCBMI remained significant.

Marju Orho-Melander, PhD, a professor of genetic epidemiology and senior investigator of the study, said, “The differences in BMI were largely explained by the differences in the levels of glutamate and BCAA. This indicates that the metabolites and gut bacteria interact, rather than being independent of each other. This means that future studies should focus more on how the composition of gut bacteria can be modified to reduce the risk of obesity and associated metabolic diseases and cardiovascular disease.” The study was published on February 1, 2018, in The Journal of Clinical Endocrinology & Metabolism.

Related Links:
Lund University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.